In a new 13D filing, Dennis Purcell‘s Aisling Capital reported lowering its stake in Agile Therapeutics Inc (NASDAQ:AGRX) to 2.28 million shares, which account for 7.9% of the company’s outstanding stock. The fund’s stake was reduced from 2.58 million shares held as of the end of June.
Agile Therapeutics Inc (NASDAQ:AGRX) is a pharmaceutical company that produces women’s health products, such as contraceptives. Over the past 12 months, the company’s stock has gained 1.39%. For the second quarter of 2016, Agile Therapeutics reported a loss per share of $0.29, and a net loss of $8.42 million, compared to a loss per share of $0.38 and a net loss of $8.49 million for the same quarter of the previous year.
Image Point Fr/Shutterstock.com
Eight investors in our database were bullish on Agile Therapeutics Inc (NASDAQ:AGRX) at the end of June, same as a quarter earlier. Some of the smart managers that reported long positions in the company as of June 30 included Phill Gross and Robert Atchinson’s Adage Capital Management, which held a position worth $12.94 million, Joseph Edelman’s Perceptive Advisors, with a position valued at $3.91 million, Chuck Royce’s Royce & Associates, James E. Flynn’s Deerfield Management, and Peter Kolchinsky’s RA Capital Management.
Follow Agile Therapeutics Inc (NASDAQ:AGRX) Follow Agile Therapeutics Inc (NASDAQ:AGRX) We may use your email to send marketing emails about our services. Click here to read our privacy policy. You can access the original SEC filing by clicking here.
Subscribe to Insider Monkey's Free Daily Newsletter and Join 70K+ Readers
We may use your email to send marketing emails about our services. Click here to read our privacy policy. Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|
| Aisling Capital III | 2,275,455 | 0 | 2,275,455 | 0 | 2,275,455 | 7.9% |
| Aisling Capital Partners III | 2,275,455 | 0 | 2,275,455 | 0 | 2,275,455 | 7.9% |
| Aisling Capital Partners III | 2,275,455 | 0 | 2,275,455 | 0 | 2,275,455 | 7.9% |
| Steven Elms | 961 | 2,275,455 | 961 | 2,275,455 | 2,276,416 | 7.9% |
| Dennis Purcell | 1,879 | 2,275,455 | 1,879 | 2,275,455 | 2,277,334 | 7.9% |
| Andrew Schiff | 460 | 2,275,455 | 460 | 2,275,455 | 2,275,915 | 7.9% |
Dennis Purcell
Aisling Capital We may use your email to send marketing emails about our services. Click here to read our privacy policy. Page 1 of 9 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 3)*
Agile Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
00847L100
(CUSIP Number)
Lloyd Appel
Aisling Capital
888 Seventh Avenue, 12th Floor
New York, NY 10106
(212) 651-6380
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 30, 2016
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
